The incidence of BMs is particularly high in NSCLC, with EGFR mutations or anaplastic lymphoma kinase (ALK) rearrangements with a baseline occurrence around of 30–35% in both groups [45,46]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.